AzurRx reports Phase IIa data for MS1819 in chronic pancreatitis
In September, AzurRx BioPharma Inc. (NASDAQ:AZRX) reported data from 6 patients with chronic pancreatitis in a Phase IIa trial showing that once-daily MS1819 for 48-60 days led to a >21% improvement in coefficient of fat absorption (CFA) at the highest dose level. The trial is evaluating 280, 560, 1,120 and 2,240 mg doses of MS1819 to treat malabsorption due to exocrine pancreatic insufficiency (EPI) in chronic pancreatitis. The product led to maximal absolute CFA response of 57% and “favorable trends” in Bristol stool scale, number of daily evacuations, weight of stool and fecal nitrogen assessments.
No serious adverse events were reported. The open-label, dose-escalation trial, conducted in Australia and New Zealand, is enrolling 12-15 patients...